H.C. Wainwright lowered the firm’s price target on Valneva to $20 from $23 and keeps a Buy rating on the shares following the investor day. The firm cites more conservative initial sales estimates for Ixchiq and VLA15 for the target cut. The analyst believes Valneva’s lyme disease vaccine is a potential blockbuster.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN: